Trending...
- One Night. One Encounter. A New Season Of Purpose
- We are Talker Study: 64% of AI Users Have Bought From a Brand AI Introduced, as The Invisible Shortlist Reshapes Brand Discovery
- Bountiful Bowl Aims to Raise $50,000 to Support Meals on Wheels of the Greater Lehigh Valley
BOSTON, May 20, 2024 ~ Journalist: HotSpot Therapeutics, Inc. has announced that they will be presenting additional preclinical data from their MALT1 program at the 4th American Association for Cancer Research (AACR) International Meeting. The meeting, titled "Advances in Malignant Lymphoma," will take place from June 19-22, 2024 in Philadelphia, PA.
The company, known for pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," will be sharing their findings on the highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program.
More on The PennZone
The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will take place on Thursday, June 20, 2024 from 5:30-7:30 PM ET at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.
HotSpot Therapeutics' innovative approach to targeting regulatory sites on proteins has shown promising results in their MALT1 program and could potentially lead to new treatments for non-Hodgkin lymphomas. The company's participation in the AACR International Meeting highlights their commitment to advancing cancer research and finding new ways to treat this disease.
The company, known for pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," will be sharing their findings on the highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program.
More on The PennZone
- Pursant Founder Mark Herbick Joins STS Capital Partners as CEO
- Tampa Holiday Sessions: Captured by Mallary Opens 2026 Christmas Minis With Two New Sets
- Tampa Web Design Launches New Website for Entrepreneur and Capital Markets Advisor Martin Sumichrast
- Miami Dade College and World Affairs Council of Miami announce Navarro-Cabrera scholarship
- Bridging Canvas and Cosmos: How Bioengineer Farin DeBose Captured the Essence of "True Science"
The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will take place on Thursday, June 20, 2024 from 5:30-7:30 PM ET at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.
HotSpot Therapeutics' innovative approach to targeting regulatory sites on proteins has shown promising results in their MALT1 program and could potentially lead to new treatments for non-Hodgkin lymphomas. The company's participation in the AACR International Meeting highlights their commitment to advancing cancer research and finding new ways to treat this disease.
0 Comments
Latest on The PennZone
- The Robert Travers Team of Long & Foster Marks 300+ Homes Sold, Expands Seller Representation
- CLINIMED Becomes First Liposuction Cannula Maker to Offer 3D and AR Models of Its Cannula Range
- RAS AP Consulting Advances 1099 Education and Readiness Initiative Through IFOL Training and Finance Technology Showcase
- Heritage at Manalapan Announces New 3.875% First-Year Mortgage Rate Buydown (7.11 APR)
- Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers"
- AthleteMerch.com Surpasses 100,000 Custom Items Delivered to Fans Nationwide
- MoMojo Records Signs Gary Nicholson
- Steve Weclew is Appointed by STS Capital Partners as Managing Director
- Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders
- New Finnish Affiliate Site Ilmaiskierrokset.com Puts Wager-Free Spins in the Spotlight
- Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
- Veterans Day Breakfast Celebration in Valley Forge to Honor America's Military Heroes
- Best Black Friday 2026 Deals on Lightweight Foldable Electric Wheelchairs – Save Up to 60%
- Immerse Yourself in the Historic Tochigi Autumn Festival, Celebrated Every Two Years Since 1874
- Resident Inspect Expands Virtual Property Inspections With AppFolio and Rentvine Integrations
- Unlocking the Next Phase of Growth with New AI Innovations; Targeting 2027 as Breakeven; Revenue Momentum Accelerates: ZenaTech (N A S D A Q: ZENA)
- Dr. Marilyn Pendelton Releases The Grief Reset to Address Grief Beyond Death
- AeroNet Deploys netElastic vBNG and CGNAT with Tarana Wireless to Deliver Scalable, Fiber-Class Broadband Across Puerto Rico
- New Atlas Maps the 38 States Behind Every Conversation
- Atlanta Company Launches Free, Ad-Free, Nonpartisan Voter Planning App for All 50 States Ahead of the Nov. 3 Election